spacer
home > ebr > spring 2002 > a record-breaking us$27 billion of biotech deals supports strong pharma m&a activity in 2001
PUBLICATIONS
European Biopharmaceutical Review

A Record-Breaking US$27 Billion of Biotech Deals Supports Strong Pharma M&A Activity in 2001

The value of pharmaceutical mergers and acquisitions (M&A) in 2001 almost doubled to US$61 billion from US$34 billion in 2000 (excluding the US$76 billion formation that year of GlaxoSmithKline), bucking the significant downward trend witnessed in most other sectors. The number of deals remained stable at 334 in 2001, compared with 341 in 2000. In a period where most industries have experienced at least a 25 per cent downturn in M&A activity, the pharmaceutical sector has maintained its deal-making momentum. The aggregate value of deals is down because 2001 witnessed no mega-mergers to rival the prior year combination of Glaxo Wellcome and SmithKline Beecham. But with Amgen's US$17 billion bid for Immunex, plus a further US$10 billion of biotech deals in 2001, the foundations are being laid for a Big Biotech sector that will increasingly compete with Big Pharma.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Neal Ransome, Partner at PricewaterhouseCoopers Corporate Finance

Neal Ransome is European leader of PricewaterhouseCoopers' Pharmaceuticals and Healthcare Corporate Finance team. He has over 10 years' experience of corporate finance transactions, and has been focusing on the pharma and health care sectors since 1997. Neal's clients in the sector have included large pharmacos such as GlaxoSmithKline and Aventis, emerging companies such as Powderject and a wide range of smaller clients in the health care and biotech sectors.
Neal has also acted for a large number of private equity clients in the sector, including 3i, Warburg Pincus and Mercury. The European team which he leads comprises approximately 20 professional staff, located in all key financial centres, and combines corporate finance experts with recruits from the industry.

spacer
Neal Ransome
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Memo Therapeutics AG sign a Development and Manufacturing Agreement

Vilnius, Lithuania, and Zurich, Switzerland – June 25, 2020 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Swiss biotech company Memo Therapeutics AG have signed a Development and Manufacturing Agreement for a therapeutic antibody.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement